A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This is a multicenter, randomized, open-label Phase 2 study designed to evaluate safety and tolerability and preliminary efficacy of VS-6766 versus VS-6766 in combination with defactinib in subjects with molecularly profiled recurrent LGSOC.
This is a multicenter, randomized, open-label Phase 2 study designed to evaluate safety and tolerability and preliminary efficacy of VS-6766 versus VS-6766 in combination with defactinib in subjects with molecularly profiled recurrent LGSOC.
Tracking Information
- NCT #
- NCT04625270
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- GOG Foundation
- Investigators
- Principal Investigator: Susana Banerjee, MBBS,MA,PhD European Network of Gynaecological Oncological Trial Groups (ENGOT) Principal Investigator: Rachel Grisham, MD GOG Foundation Study Director: Hagop Youssoufian, MSc, MD Verastem, Inc.
Get Well Soon